The proportion of subjects reporting an equal or better outcome for the side of face treated with Belotero® Basic compared to the side of face treated with Juvéderm® Ultra 3 at V4 on the validated Wrinkle Severity Rating Scale II Week 4 [clinicaltrials_resource:25c38beb952fcf2689231e7e8919fbb7]
The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The proportion of subjects reporting an equal or better outcome for the side of face treated with Belotero® Basic compared to the side of face treated with Juvéderm® Ultra 3 at V4 on the validated Wrinkle Severity Rating Scale II Week 4 [clinicaltrials_resource:25c38beb952fcf2689231e7e8919fbb7]
The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
Bio2RDF identifier
25c38beb952fcf2689231e7e8919fbb7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:25c38beb952fcf2689231e7e8919fbb7
measure [clinicaltrials_vocabulary:measure]
The proportion of subjects rep ...... inkle Severity Rating Scale II
time frame [clinicaltrials_vocabulary:time-frame]
description
The dosage is individualized d ...... ht and Juvéderm® Ultra 3 left.
identifier
clinicaltrials_resource:25c38beb952fcf2689231e7e8919fbb7
title
The proportion of subjects rep ...... everity Rating Scale II Week 4
@en
type
label
The proportion of subjects rep ...... 38beb952fcf2689231e7e8919fbb7]
@en